Further studies to identify the protein that directly binds to UBE2T and activates the AKT/GSK3β/β-catenin pathway in NPC will not only further elucidate the mechanism of UBE2T activity, but also provide a novel therapeutic target for NPC. The gene discussed is AKT1; the disease is nasopharyngeal carcinoma.